VerImmune Inc (www.verimmune.com) is a biotechnology company developing a novel Virus-inspired Particle (ViP™) platform delivery technology that can be used to treat multiple diseases. Their lead program is in oncology, where the ViP redirects immune memory against pathogens to target cancer. The targeting of tumors stems from the ViP being specific to a tumor-associated heparin sulfate chain that is expressed across many tumors, making it a potential treatment for a wide variety of solid tumors. This highly novel and differentiated approach has allowed the company to foster partnerships with Janssen Biologics (J&J) and Fosun Pharma USA. Beyond Oncology, VerImmune is applying HTS and AI technology to discover and develop additional ViP vectors with novel delivery properties, enabling the treatment of many more diseases and serving more patients.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
DC
Company HQ Country:
United States
Year Founded:
Dec 2019
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
VERI-101
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
